Janssen posts results of Phase 3 ustekinumab trial in pediatric ulcerative colitis
The study, completed in 2025, enrolled 112 pediatric participants with moderately to severely active ulcerative colitis and evaluated ustekinumab induction and maintenance therapy. Results were first posted on ClinicalTrials.gov on October 20, 2026.
Primary source
ClinicalTrials.gov results record, October 20, 2026
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Read the source: A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation